Jeongshim Lee1, Chul Yong Kim2, Woong Sub Koom3, Chai Hong Rim4. 1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Radiation Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea. 2. Department of Radiation Oncology, Anam Hospital, Korea University Medical College, Seoul, Republic of Korea. 3. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea. 4. Department of Radiation Oncology, Ansan Hospital, Korea University Medical College, Ansan, Republic of Korea. Electronic address: crusion3@naver.com.
Abstract
BACKGROUND AND PURPOSE: Re-irradiation might yield local control (LC) or palliation for locoregionally recurrent rectal cancer (LRRC), but iatrogenic complications are a possible hindrance. We aimed to evaluate the efficacy of re-irradiation to determine optimal treatment of LRRC. METHODS: We performed a systematic review of PubMed, MEDLINE, Cochrane Library, and Embase. RESULTS: A total of 17 studies involving 744 patients with LRRC were included; median OS ranging from 10 to 45 months (median: 24.5 months). Pooled 1-, 2-, and 3-year OS rates for all patients were 76.1%, 49.1%, and 38.3%, respectively. For patients who underwent re-irradiation and surgery (OP group), these pooled rates were 85.9%, 71.8%, and 51.7%, respectively. For patients who underwent re-irradiation but not surgery (non-OP group), pooled 1-, 2-, and 3-year OS rates were 63.5%, 34.2%, and 23.8%, respectively. The OS difference between both groups was significant for all 3 years (P < 0.05). Pooled 1-, 2-, and 3-year LC rates for the OP group were 84.4%, 63.8%, and 46.9%, and for the non-OP group were 72.0%, 54.8%, and 44.6%, respectively, without significant differences. Pooled grade ≥3 acute and late complication rates were 11.7% and 25.5% in the OP and non-OP groups, respectively. Patients who underwent surgery had a higher risk of grade ≥3 late complications (odds ratio: 6.39). Pooled symptomatic palliation rate was 75.2%. CONCLUSIONS: Re-irradiation with or without surgery for LRRC showed oncologic and palliative efficacy. Salvage treatment including re-irradiation and surgery showed higher survival, but the late complication was significantly increased with concomitant surgery.
BACKGROUND AND PURPOSE: Re-irradiation might yield local control (LC) or palliation for locoregionally recurrent rectal cancer (LRRC), but iatrogenic complications are a possible hindrance. We aimed to evaluate the efficacy of re-irradiation to determine optimal treatment of LRRC. METHODS: We performed a systematic review of PubMed, MEDLINE, Cochrane Library, and Embase. RESULTS: A total of 17 studies involving 744 patients with LRRC were included; median OS ranging from 10 to 45 months (median: 24.5 months). Pooled 1-, 2-, and 3-year OS rates for all patients were 76.1%, 49.1%, and 38.3%, respectively. For patients who underwent re-irradiation and surgery (OP group), these pooled rates were 85.9%, 71.8%, and 51.7%, respectively. For patients who underwent re-irradiation but not surgery (non-OP group), pooled 1-, 2-, and 3-year OS rates were 63.5%, 34.2%, and 23.8%, respectively. The OS difference between both groups was significant for all 3 years (P < 0.05). Pooled 1-, 2-, and 3-year LC rates for the OP group were 84.4%, 63.8%, and 46.9%, and for the non-OP group were 72.0%, 54.8%, and 44.6%, respectively, without significant differences. Pooled grade ≥3 acute and late complication rates were 11.7% and 25.5% in the OP and non-OP groups, respectively. Patients who underwent surgery had a higher risk of grade ≥3 late complications (odds ratio: 6.39). Pooled symptomatic palliation rate was 75.2%. CONCLUSIONS: Re-irradiation with or without surgery for LRRC showed oncologic and palliative efficacy. Salvage treatment including re-irradiation and surgery showed higher survival, but the late complication was significantly increased with concomitant surgery.
Authors: Thomas Smith; Sean M O'Cathail; Sabrina Silverman; Maxwell Robinson; Yatman Tsang; Mark Harrison; Maria A Hawkins Journal: Adv Radiat Oncol Date: 2020-08-07
Authors: Esmée A Dijkstra; Véronique E M Mul; Patrick H J Hemmer; Klaas Havenga; Geke A P Hospers; Christina T Muijs; Boudewijn van Etten Journal: Ann Surg Oncol Date: 2021-05-22 Impact factor: 5.344
Authors: R Chuter; E Glassborow; R Speight; M Clarke; L Murray; G Radhakrishna; V Lavin; L Aspin; M Aldred; S Gregory; J Richardson; J Handley Journal: Phys Imaging Radiat Oncol Date: 2022-02-23